Role of the nitric oxide-cyclic GMP-K+ channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac

Proceedings of the Western Pharmacology Society

Volumn 45, Issue , 2002, Pages 174-177

  Ortiz, Mario I ^a   Torres López, Jorge E ^a   Castañeda Hernández, Gilberto ^a   Rosas, Rodolfo ^a   Vidal Cantú, Guadalupe C ^a   Granados Soto, Vinicio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DICLOFENAC; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHANNEL; POTASSIUM ION; 1H (1,2,4)OXADIAZOLO(4,3 A)QUINOXALIN 1 ONE; 1H-(1,2,4)OXADIAZOLO(4,3-A)QUINOXALIN-1-ONE; ANALGESIC AGENT; CHARYBDOTOXIN; DIAGNOSTIC AGENT; ENZYME INHIBITOR; FORMALDEHYDE; GLIBENCLAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OXADIAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; TOLBUTAMIDE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; NOCICEPTION; NONHUMAN; PAIN; RAT; ANIMAL; ARTICLE; DRUG ANTAGONISM; METABOLISM; PAIN ASSESSMENT; PHYSIOLOGY; WISTAR RAT;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATRIAL NATRIURETIC FACTOR; CHARYBDOTOXIN; CYCLIC GMP; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FORMALDEHYDE; GLYBURIDE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXADIAZOLES; PAIN MEASUREMENT; POTASSIUM CHANNELS; QUINOXALINES; RATS; RATS, WISTAR; TOLBUTAMIDE;

EID: 1842855124     PISSN: 00838969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Menasse R, Hedwell PR, Kraetz J, Pericin C, Riesterer L, Sallmann A, Ziel R & Jaques R: Scand J Rheumatol (Suppl 22): 5 (1978).
2. Todd PA & Sorkin EM: Drugs 35: 244 (1988).
3. Krupp PJ, Menasse-Ginia R, Sallmann A, Wilhelmi G, Ziel R & Jaques R: Experientia 29: 450 (1973).
4. Ku EC, Wasvary JM & Cash WD: Pharmacol 24: 641 (1975).
5. Oliw E, Lundén I & Anggard E: Acta Pharmacol Toxicol 42: 179 (1978).
6. Attal N, Kayser V, Echalier A, Benoist JM & Guilbaud G: Pain 25: 341 (1988).
7. Björkman R: Acta Anaesthesiol Scand (Suppl 103) 39: 1 (1995).
8. Yamamoto T & Nozaki-Taguchi N: Brain Res 739: 104 (1996).
9. Chapman V & Dickenson AH: Eur J Pharmacol 219: 427 (1992).
10. Ferreira SH, Lorenzetti BB & Correa FMA: Eur J Pharmacol 53: 39 (1978).
11. Wada Y, Etoh Y, Ohira A, Kimata H, Koide T, Ishihama H & Mizushima: J Phar Pharmacol 34: 467 (1981).
12. Tonussi CR & Ferreira SH: Eur J Pharmacol 251: 173 (1994).
13. López-Muñoz FJ, Castañeda-Hernández G, Torres-López JE, Picazo YF, Flores-Murrieta FJ & Granados-Soto V: Pharm Sci 2: 189 (1996).
14. Granados-Soto V, Flores-Murrieta FJ, Castañeda-Hernández G & López-Muñoz FJ: Eur J Pharmacol 277: 281 (1995).
15. Lorenzetti BB & Ferreira SH: Inflamm Res 45: 308 (1996).
16. Aguirre-Bañuelos P & Granados-Soto V: Eur J Pharmacol 395: 9 (2000).
17. Kourie JI & Rive MJ: Med Res Rev 19: 75 (1999).
18. Waldman SA & Murad F: Pharmacol Rev 39: 163 (1987).
19. Edwards G & Weston AH: Annu Rev Pharmacol Toxicol 33: 597 (1993).
20. Ortiz MI, Castañeda-Hernández G, Rosas R, Vidal-Cantú GC & Granados-Soto V: Proc West Pharmacol Soc 44: 19 (2001).
21. Lazaro-Ibañez GG, Torres-Lopez JE & Granados-Soto: Eur J Pharmacol 426: 39 (2001).
22. IASP: Pain 16: 109 (1983).
23. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW & Moncada S: Proc Natl Acad Sci USA 93: 1480 (1996).
24. Rees DD, Palmer RMS, Schulz R, Hodson HF & Moncada S: Br J Pharmacol 101: 746 (1990).
25. Sah P: Trends Neurosci 19: 150 (1996).
26. Vane JR & Botting RM: Scand J Rheumatol (Suppl 102) 25: 9 (1996).
27. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA & Vane JR: Proc Natl Acad Sci USA 96: 7563 (1999).